Department of Internal Medicine, Creighton University School of Medicine, Omaha, NE.
Department of Internal Medicine, Creighton University School of Medicine, Omaha, NE.
Cardiovasc Revasc Med. 2022 Apr;37:68-75. doi: 10.1016/j.carrev.2021.06.017. Epub 2021 Jun 19.
Patients with diabetes mellitus (DM) have a high prevalence of coronary chronic total occlusions (CTOs). We conducted a systematic review and meta-analysis to characterize outcomes after CTO percutaneous coronary intervention (PCI) in patients without or with DM.
PubMed, EMBASE, Cochrane, and Google Scholar were queried for studies comparing non-DM vs. DM patients undergoing attempted CTO PCI. The primary outcome was all-cause mortality at longest follow-up (at least 6 months). Secondary outcomes were major adverse cardiovascular events (MACE) which is a composite endpoint including myocardial infarction, cardiac or all-cause mortality and any revascularization in patients after CTO PCI, target vessel revascularization (TVR), myocardial infarction (MI), Japanese chronic total occlusion (J-CTO) score and prevalence of multivessel (MV) CTO disease. We used a random effects model to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Sixteen studies, including 2 randomized control trials and 14 observational studies, met inclusion criteria. At longest follow-up, all-cause mortality (OR 0.54 [95% CI 0.37-0.80], p < 0.0001) and MACE (OR 0.82 [95% CI 0.72-0.93], p < 0.00001) were significantly lower in non-DM CTO patients. MV CTO disease was less prevalent in patients without DM (OR 0.80 [95% CI 0.69-0.93], p = 0.004). However, there were no differences in MI, TVR and J-CTO score.
Non-diabetics undergoing CTO PCI have lower all-cause mortality and MACE than diabetics. Future research may determine if DM control improves diabetics' CTO PCI outcomes.
患有糖尿病(DM)的患者冠状动脉慢性完全闭塞(CTO)的患病率较高。我们进行了系统评价和荟萃分析,以描述无糖尿病或有糖尿病的患者接受 CTO 经皮冠状动脉介入治疗(PCI)后的结局。
检索 PubMed、EMBASE、Cochrane 和 Google Scholar,以比较尝试进行 CTO PCI 的非糖尿病患者与糖尿病患者的研究。主要结局是最长随访时间(至少 6 个月)的全因死亡率。次要结局是主要不良心血管事件(MACE),这是一个复合终点,包括心肌梗死、心脏或全因死亡率以及 CTO PCI 后患者的任何血运重建、靶血管血运重建(TVR)、心肌梗死(MI)、日本 CTO 评分和多血管(MV)CTO 疾病的患病率。我们使用随机效应模型计算比值比(OR)和 95%置信区间(CI)。
符合纳入标准的研究有 16 项,包括 2 项随机对照试验和 14 项观察性研究。在最长随访时间内,非糖尿病 CTO 患者的全因死亡率(OR 0.54 [95%CI 0.37-0.80],p<0.0001)和 MACE(OR 0.82 [95%CI 0.72-0.93],p<0.00001)明显较低。无糖尿病患者 MV CTO 疾病的患病率较低(OR 0.80 [95%CI 0.69-0.93],p=0.004)。然而,MI、TVR 和 J-CTO 评分没有差异。
接受 CTO PCI 的非糖尿病患者的全因死亡率和 MACE 低于糖尿病患者。未来的研究可能会确定糖尿病控制是否能改善糖尿病患者的 CTO PCI 结局。